论文部分内容阅读
目的观察早期应用尿激酶(UK)治疗急性脑梗死的临床效果。方法选择53例发病在6h内的急性脑梗死,随机分成UK组(28例)和对照组(25例),UK组UK 150万U 30m in内静脉滴注,对照组不用UK,其余两组治疗相同。评价治疗前和治疗后14d神经功能缺损程度评分。结果UK组总有效率为92.8%,对照组84%(P<0.05);UK组基本痊愈率为60.7%,与对照组基本痊愈率24%相比差异有统计学意义(P<0.01)。个别病例出现轻度皮肤、粘膜出血,停药后症状消失,未发现严重不良反应。结论UK治疗急性脑梗死临床疗效确切、安全,不良反应轻微。
Objective To observe the clinical effect of early application of urokinase (UK) in the treatment of acute cerebral infarction. Methods Fifty-three patients with acute cerebral infarction within 6 hours were randomly divided into UK group (n = 28) and control group (n = 25). UK group received UK 1.5 million U 30 m in intravenous drip, while control group did not use UK. The other two groups The same treatment. The score of neurological impairment before and 14 days after treatment was evaluated. Results The total effective rate was 92.8% in the UK group and 84% in the control group (P <0.05). The basic cure rate in the UK group was 60.7%, which was significantly different from that in the control group (24%) (P <0.01). Individual cases of mild skin, mucous membrane bleeding, symptoms disappeared after stopping, did not find serious adverse reactions. Conclusion UK clinical efficacy of acute cerebral infarction is accurate, safe, minor adverse reactions.